Innovation in Pharmaceutical Assistance

Jean Leandro Dos Santos

doi:10.1590/s2175-97902022e19724

Authors

Jean Leandro Dos Santos School of Pharmaceutical Science, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil https://orcid.org/0000-0002-2460-2829

DOI:

https://doi.org/10.1590/s2175-97902022e19724

Keywords:

Innovation, Drug discovery, Pharmaceutical care, Pharmaceutical assistance, Novel drugs

Abstract

Innovation is the driving force that is able to create and transform products, processes, and organization in the health system. Innovation in the field of pharmaceutical assistance covers a wide spectrum of aspects, from drug discovery to pharmaceutical care, contributing to the improvement in treatments through novel drugs or methods. This work will present the major characteristics of innovation with special emphasis on aspects pertaining to pharmaceutical assistance. The types and models of innovation, as well as the interaction between academia and industry, will be presented with examples of successful products and methods. In addition, the challenges and perspectives for innovation in pharmaceutical assistance will be discussed with a focus on drug discovery.

Downloads

Download data is not yet available.

References

Abou-Gharbia M, Childers WE. Discovery of innovative therapeutics: today’s realities and tomorrow’s vision. 2. Pharma’s challenges and their commitment to innovation. J Med Chem. 2014;57(13):5525-53.

Alt S, Helmstädter A. Market entry, power, pharmacokinetics: what makes a successful drug innovation? Drug Discov Today. 2018;23(2):208-12.

Bennani YL. Drug discovery in the next decade: innovation needed ASAP. Drug Discov Today . 2011;16(17-18):779-92.

Bentley A, Butters M, Green SP, Learmonth WJ, MacRae JA, Morland MC, et al. The Discovery and Process Development of a Commercial Route to the Water Soluble Prodrug, Fosfluconazole. Org Process Res Dev. 2002;6(2):109-12.

Bentzien J, Bharadwaj R, Thompson DC. Crowdsourcing in pharma: a strategic framework. Drug Discov Today . 2015;20(7):874-83.

Bleed D, Dye C, Raviglione MC. Dynamics and control of the global tuberculosis epidemic. Curr Opin Pulm Med. 2000;6(3):174-9.

Brasil. Lei no 10.973, de 2 de dezembro de 2004. Dispõe sobre incentivos à inovação e à pesquisa científica e tecnológica no ambiente produtivo e dá outras providências. Diário Oficial da União 3 dez 2004; Seção 1.

Brasil. Decreto no 9.283, de 7 de fevereiro de 2018. Estabelece medidas de incentivo à inovação e à pesquisa científica e tecnológica no ambiente produtivo, com vistas à capacitação tecnológica, ao alcance da autonomia tecnológica e ao desenvolvimento do sistema. Diário Oficial da União 6 fev 2018; Seção 1.

Chesbrough H, Chen EL. Using Inside-Out Open Innovation to Recover Abandoned Pharmaceutical Compounds. J Innov Manag. 2015;3(2):21.

Chesbrough HW. Open Innovation The New Imperative for Creating and Profiting from Technology. Boston: Harvard Business Press; 2003. 13 p.

Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 2010;85(1):39-58.

De Clercq E. An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta Pharm Sin B. 2015;5(6):520-43.

DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151-85.

Dutra LA, Heidenreich D, Silva GDBD, Chung MC, Knapp S, Santos JLD. Dietary compound resveratrol is a Pan-BET Bromodomain inhibitor. Nutrients. 2017;9(11):E1172.

Enkel E, Gassmann O, Chesbrough H. Open Innovation: The New Imperative for Creating and Profiting from Technology. R&D Manag. 2009;39(4):311-6.

Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide. Cancer Gene Ther. 2000;7(2):233-9.

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010; 468(7327):1067-73.

Frearson J, Wyatt P. Drug discovery in academia: the third way? Expert Opin Drug Discov. 2010;5(10):909-19.

Frye S, Crosby M, Edwards T, Juliano R. US academic drug discovery. Nat Rev Drug Discov. 2011;10(6):409-10.

Grzybowski S. Natural history of tuberculosis. Epidemiology. Bull Int Union Tuberc Lung Dis. 1991;66(4):193-4.

Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004;9(5):482-8.

Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. Am J Cardiol. 2017;120(10):1813-9.

Hughes B. Pharma pursues novel models for academic collaboration. Nat Rev Drug Discov . 2008;7(8):631-2.

Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov . 2010;9(11):867-82.

Mao Y, Tian G, Liu Z, Shen J, Shen J. An improved synthetic route for preparative process of vardenafil. Org Process Res Dev . 2009;13(6):1206-8.

Melese T, Lin SM, Chang JL, Cohen NH. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med. 2009;15(5):502-7.

Mendes GD, dos Santos Filho HO, dos Santos Pereira A, Mendes FD, Ilha JO, Alkharfy KM, et al. A Phase I clinical trial of lodenafil carbonate, a new phosphodiesterase Type 5 (PDE5) inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 2012;50(12):896-906.

Mullard A. Do you want chips with that? Nat Rev Drug Discov . 2015;14(11):735-7.

Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23(1):35-61.

Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov . 2011;10(6):428-38.

Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov . 2018;17(8):559-87.

Roy V, King L. Betting on hepatitis C: how financial speculation in drug development influences access to medicines. BMJ. 2016;354:i3718.

Schuhmacher A, Gassmann O, Hinder M. Changing R&D models in research-based pharmaceutical companies. J Transl Med. 2016;14(1):105.

Schuhmacher A, Germann P-G, Trill H, Gassmann O. Models for open innovation in the pharmaceutical industry. Drug Discov Today . 2013;18(23-24):1133-7.

Scott AR. Chemical probes: A shared toolbox. Nature . 2016;533(7602):S60-1.

Silverman RB. From basic science to blockbuster drug: the discovery of Lyrica. Angew Chem Int Ed Engl. 2008;47(19):3500-4.

Soratto J, Pires DEP de, Dornelles S, Lorenzetti J, Soratto J, Pires DEP de, et al. Family health strategy: a technological innovation in health. Texto Context - Enferm. 2015;24(2):584-92.

Steinberg G, Kuznetsov D, O’Connor R, Alsikafi N. Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. Expert Opin Pharmacother. 2001;2(6):1009-13.

Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017;11(1):27-37.

Sudo RT, Simonetti MDPB, Russo VFT, Russo EMDS. Levobupivacaine pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and their use. Patent EP1276480B1. Cristália Produtos Químicos Farmacêuticos Ltda; 2001.

Taylor FW. Principles of Scientific Management. New York: Harper & Row; 1911. 156 p.

Taylor EC, Patel HH. Synthesis of pyrazolo 3,4-dpyrimidine analogues of the potent agent N-4-2-2-amino-4 3H-oxo-7H-pyrrolo 2,3-dpyrimidin-5-yl ethylbenzoyl-L-glutamic acid (LY231514). Tetrahedron. 1992;48(37):8089-100.

Tian G, Liu Z, Zheng J, Shen J. N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)benzenesulfonyl)-4,5-dihydro-5-oxo-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof. Patent EP2228370B1. Topharman Shanghai Co. Ltda; 2007.

Tigre PB. Gestão da inovação: uma abordagem estratégica, organizacional e de gestão de conhecimento. Rio de Janeiro: Elsevier; 2014. 296 p.

Yamanaka T, Kano S. Mapping lifecycle management activities for blockbuster drugs in Japan based on drug approvals and patent term extensions. Drug Discov Today . 2016;21(2):306-14.

Innovation in Pharmaceutical Assistance

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

Issue

Section

License

How to Cite

Funding data